163 related articles for article (PubMed ID: 23240672)
1. High-grade endometrial carcinomas - strategies for typing.
Soslow RA
Histopathology; 2013 Jan; 62(1):89-110. PubMed ID: 23240672
[TBL] [Abstract][Full Text] [Related]
2. Use of mutation profiles to refine the classification of endometrial carcinomas.
McConechy MK; Ding J; Cheang MC; Wiegand K; Senz J; Tone A; Yang W; Prentice L; Tse K; Zeng T; McDonald H; Schmidt AP; Mutch DG; McAlpine JN; Hirst M; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
J Pathol; 2012 Sep; 228(1):20-30. PubMed ID: 22653804
[TBL] [Abstract][Full Text] [Related]
3. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical characterization of endometrial carcinomas: endometrioid, serous and clear cell adenocarcinomas in association with genetic analysis.
Yasuda M
J Obstet Gynaecol Res; 2014 Dec; 40(12):2167-76. PubMed ID: 25363801
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor.
Hoang LN; Han G; McConechy M; Lau S; Chow C; Gilks CB; Huntsman DG; Köbel M; Lee CH
Histopathology; 2014 Mar; 64(4):585-96. PubMed ID: 24103020
[TBL] [Abstract][Full Text] [Related]
6. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
7. IMP2 expression distinguishes endometrioid from serous endometrial adenocarcinomas.
Zhang L; Liu Y; Hao S; Woda BA; Lu D
Am J Surg Pathol; 2011 Jun; 35(6):868-72. PubMed ID: 21566514
[TBL] [Abstract][Full Text] [Related]
8. [Application of immunohistochemistry in differential diagnosis of endometrial carcinoma].
Wu HW; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2012 Nov; 41(11):784-8. PubMed ID: 23302346
[No Abstract] [Full Text] [Related]
9. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
[TBL] [Abstract][Full Text] [Related]
10. Strategies for distinguishing low-grade endometrioid and serous carcinomas of endometrium.
Garg K; Soslow RA
Adv Anat Pathol; 2012 Jan; 19(1):1-10. PubMed ID: 22156830
[TBL] [Abstract][Full Text] [Related]
11. HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis.
McCluggage WG; Connolly LE; McBride HA; Kalloger S; Gilks CB
Histopathology; 2012 Mar; 60(4):547-53. PubMed ID: 22250726
[TBL] [Abstract][Full Text] [Related]
12. Mammaglobin expression in gynecologic adenocarcinomas.
Hagemann IS; Pfeifer JD; Cao D
Hum Pathol; 2013 Apr; 44(4):628-35. PubMed ID: 23084633
[TBL] [Abstract][Full Text] [Related]
13. Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type.
Clarke BA; Gilks CB
J Clin Pathol; 2010 May; 63(5):410-5. PubMed ID: 20418232
[TBL] [Abstract][Full Text] [Related]
14. Utility of hepatocyte nuclear factor-1β as a diagnostic marker in ovarian carcinomas with clear cells.
Kao YC; Lin MC; Lin WC; Jeng YM; Mao TL
Histopathology; 2012 Nov; 61(5):760-8. PubMed ID: 22747504
[TBL] [Abstract][Full Text] [Related]
15. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype.
Schlosshauer PW; Ellenson LH; Soslow RA
Mod Pathol; 2002 Oct; 15(10):1032-7. PubMed ID: 12379748
[TBL] [Abstract][Full Text] [Related]
16. Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma.
Sobel G; Németh J; Kiss A; Lotz G; Szabó I; Udvarhelyi N; Schaff Z; Páska C
Gynecol Oncol; 2006 Nov; 103(2):591-8. PubMed ID: 16797678
[TBL] [Abstract][Full Text] [Related]
17. cDNA microarray analysis and immunohistochemistry reveal a distinct molecular phenotype in serous endometrial cancer compared to endometrioid endometrial cancer.
Chen Y; Yao Y; Zhang L; Li X; Wang Y; Zhao L; Wang J; Wang G; Shen D; Wei L; Zhao J
Exp Mol Pathol; 2011 Aug; 91(1):373-84. PubMed ID: 21540026
[TBL] [Abstract][Full Text] [Related]
18. Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis.
Romero-Pérez L; Castilla MÁ; López-García MÁ; Díaz-Martín J; Biscuola M; Ramiro-Fuentes S; Oliva E; Matias-Guiu X; Prat J; Cano A; Moreno-Bueno G; Palacios J
Hum Pathol; 2013 Feb; 44(2):244-54. PubMed ID: 22974476
[TBL] [Abstract][Full Text] [Related]
19. Comparative Use of Napsin A and Glypican 3 to Distinguish Endometrial Clear Cell from Serous and Endometrioid Carcinomas.
Miller EM; Tymon-Rosario J; Sunkara J; Harmon BE; Karabakhtsian RG; Novetsky AP
Int J Gynecol Cancer; 2018 Sep; 28(7):1318-1324. PubMed ID: 30036224
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]